BioNTech SE - ADR Aktie News

BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.

The pharmaceutical firm has been hit hard as demand for Covid-19 vaccines plunged.

BioNTech SE (NASDAQ: BNTX) is down nearly 5.0% in premarket on Wednesday after reporting disappointing financial results for the fourth quarter. BioNTech stock down on muted guidance The stock is being hit because $BNTX did not issue an impressive guidance either.

Shares of BioNTech SE BNTX, +1.22% dropped 4.4% in premarket trading Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply to miss expectations, weighed down by inventory writedowns by COVID-19 vaccine collaboration partner Pfizer Inc. PFE, -0.32% Net profit for the quarter to Dec. 31 dropped to EUR457.9 million ($496.5 million), or EUR1.90 a...

Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, reported on Wednesday a plunge in 2023 revenue and earnings as its focus shifts towards cancer drug development.

Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024 Aiming for first oncology launch in 2026 and ten indication approvals by 2030 as part of BioNTech's strategy to develop combinatorial and synergistic therapeutic approaches Entered strategic coll aborations with Biotheus, DualityBio, Medilink and...

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024. She will join BioNTech from Novartis AG (“Novartis”) and succeed Sean Marett in this role.

Investing in biopharmaceutical stocks comes with more risks than some other types of stocks.